NasdaqGS - Delayed Quote USD

Syros Pharmaceuticals, Inc. (SYRS)

5.04 -0.06 (-1.18%)
At close: April 26 at 4:00 PM EDT
4.97 -0.07 (-1.39%)
After hours: April 26 at 5:30 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Richard A. Young Ph.D. Scientific Founder, Member of Scientific Advisory Board & Director 108.37k -- 1954
Dr. David A. Roth M.D. Chief Medical Officer 679.52k -- 1963
Mr. Conley Chee CEO, President & Director -- -- 1970
Dr. James E. Bradner M.D. Founder -- -- 1972
Dr. Nathanael S. Gray Ph.D. Scientific Founder & Member of Scientific Advisory Board -- -- --
Mr. Jason Haas Chief Financial Officer 457.22k -- 1968
Ms. Karen Hunady M.S. Director of Corporate Communications & Investor Relations -- -- --
Mr. Gerald E. Quirk Esq., J.D. Chief Legal Officer & Head of Business Development 127.07k -- 1968
Ms. Lisa Roberts Vice President of Human Resources -- -- --
Ms. Kristin Stephens Chief Development Officer -- -- 1973

Syros Pharmaceuticals, Inc.

35 CambridgePark Drive
4th Floor
Cambridge, MA 02140
United States
617 744 1340 https://www.syros.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
68

Description

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Syros Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 08, 2024 - May 13, 2024
Syros Pharmaceuticals, Inc. Earnings Call

Related Tickers

GLYC GlycoMimetics, Inc.
1.6400
-4.09%
 
FGEN FibroGen, Inc.
1.0400
+1.96%
 
MGNX MacroGenics, Inc.
14.56
+1.32%
 
MCRB Seres Therapeutics, Inc.
0.8250
+11.08%
 
ADAP Adaptimmune Therapeutics plc
1.0750
+1.42%
 
BDTX Black Diamond Therapeutics, Inc.
5.89
+15.26%
 
ORIC ORIC Pharmaceuticals, Inc.
8.07
+5.22%
 
KURA Kura Oncology, Inc.
19.65
+3.42%
 
GOVX GeoVax Labs, Inc.
1.4200
-3.40%
 
TARA Protara Therapeutics, Inc.
2.9250
-4.10%